Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLRBNASDAQ:CUENASDAQ:KLRSNASDAQ:RENB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$4.82+1.9%$8.61$4.36▼$94.50$8.73M0.51142,840 shs238,953 shsCUECue Biopharma$0.69-0.6%$0.69$0.45▼$1.99$51.84M1.43406,966 shs66,632 shsKLRSKalaris Therapeutics$2.50-2.3%$0.00$2.28▼$24.15$46.75M0.4838,087 shs35,701 shsRENBRenovaro$0.28-0.5%$0.33$0.27▼$2.10$47.85M0.511.57 million shs622,484 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences+1.92%-34.67%-42.11%-39.22%-93.49%CUECue Biopharma-0.58%-12.85%+8.91%+1.91%-29.80%KLRSKalaris Therapeutics-2.34%-2.34%-18.83%+249,999,900.00%+249,999,900.00%RENBRenovaro-0.47%-20.37%-3.47%-29.19%-82.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLRBCellectar Biosciences3.5624 of 5 stars3.25.00.00.03.01.71.3CUECue Biopharma4.0958 of 5 stars3.52.00.04.72.50.80.6KLRSKalaris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARENBRenovaro1.1929 of 5 stars0.02.00.00.02.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLRBCellectar Biosciences 2.33Hold$375.007,678.47% UpsideCUECue Biopharma 3.00Buy$3.00336.05% UpsideKLRSKalaris Therapeutics 0.00N/AN/AN/ARENBRenovaro 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CLRB, CUE, KLRS, and RENB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025CLRBCellectar BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLRBCellectar BiosciencesN/AN/AN/AN/A$8.98 per shareN/ACUECue Biopharma$9.29M5.58N/AN/A$0.28 per share2.46KLRSKalaris TherapeuticsN/AN/AN/AN/A$22.47 per shareN/ARENBRenovaroN/AN/AN/AN/A$0.89 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLRBCellectar Biosciences-$44.58M-$21.92N/AN/AN/AN/A-619.70%-158.04%8/11/2025 (Estimated)CUECue Biopharma-$40.67M-$0.67N/AN/AN/A-507.87%-228.43%-114.66%8/13/2025 (Estimated)KLRSKalaris Therapeutics-$58.77MN/A0.00∞N/AN/A-62.08%-54.69%N/ARENBRenovaro-$88.43M-$0.77N/A∞N/AN/A-60.38%-47.04%N/ALatest CLRB, CUE, KLRS, and RENB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CLRBCellectar Biosciences-$5.10-$3.90+$1.20-$0.14N/AN/A5/12/2025Q1 2025CUECue Biopharma-$0.14-$0.17-$0.03-$0.17$0.90 million$0.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLRBCellectar BiosciencesN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/AKLRSKalaris TherapeuticsN/AN/AN/AN/AN/ARENBRenovaroN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLRBCellectar BiosciencesN/A2.472.47CUECue BiopharmaN/A1.031.03KLRSKalaris TherapeuticsN/A14.3114.31RENBRenovaroN/A0.130.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLRBCellectar Biosciences16.41%CUECue Biopharma35.04%KLRSKalaris Therapeutics66.05%RENBRenovaro71.41%Insider OwnershipCompanyInsider OwnershipCLRBCellectar Biosciences5.04%CUECue Biopharma10.78%KLRSKalaris Therapeutics32.07%RENBRenovaro21.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLRBCellectar Biosciences101.81 million1.72 millionOptionableCUECue Biopharma6075.35 million67.23 millionOptionableKLRSKalaris Therapeutics11018.70 million12.70 millionN/ARENBRenovaro20172.12 million134.74 millionOptionableCLRB, CUE, KLRS, and RENB HeadlinesRecent News About These CompaniesRenovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - NasdaqJuly 2 at 9:52 PM | nasdaq.comRenovaro Biosciences: Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - FinanzNachrichten.deJuly 2 at 11:49 AM | finanznachrichten.deRenovaro (NASDAQ:RENB) Stock Price Down 1.3% - Here's WhyJuly 1 at 2:33 AM | americanbankingnews.comRenovaro (NASDAQ:RENB) Shares Down 1.3% - Time to Sell?July 1 at 2:32 AM | marketbeat.comRenovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security NeedsJune 30, 2025 | accessnewswire.comARenovaro subsidiary secures patent for drug discovery AIJune 5, 2025 | uk.investing.comRENB-aandeel raakt 52-weeks dieptepunt van $ 0,27 door marktuitdagingenJune 5, 2025 | nl.investing.comRenovaro Obtains a U.S. Patent for its AI-Powered Platform for Medication Discovery and DiagnosticsJune 5, 2025 | msn.comRENB stock touches 52-week low at $0.27 amid market challengesJune 5, 2025 | investing.comRenovaro-dochter verkrijgt patent voor AI-gestuurde medicijnontwikkelingJune 3, 2025 | nl.investing.comRenovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics PlatformJune 3, 2025 | globenewswire.comRenovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger AgreementMay 24, 2025 | nasdaq.comRenovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology MergerMay 22, 2025 | insidermonkey.comUPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive OncologyMay 22, 2025 | globenewswire.comRenovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive OncologyMay 22, 2025 | globenewswire.comRenovaro partners with Amsterdam UMC on cancer diagnosticsMay 15, 2025 | uk.investing.comRenovaro lanceert AI-platform voor versnelling neurologische medicijnontwikkelingMay 15, 2025 | nl.investing.comRenovaro Inc. and Amsterdam UMC Enter Exclusive Collaboration to Develop Blood Platelet RNA DiagnosticsMay 15, 2025 | nasdaq.comRenovaro launches AI platform to advance neurology drug discoveryMay 15, 2025 | investing.comRenovaro Launches Augusta, an AI-Powered Precision Neurology PlatformMay 14, 2025 | globenewswire.comRenovaro gaat samenwerking aan met Amsterdam UMC voor kankerdiagnostiekMay 13, 2025 | nl.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLRB, CUE, KLRS, and RENB Company DescriptionsCellectar Biosciences NASDAQ:CLRB$4.82 +0.09 (+1.92%) Closing price 07/3/2025 03:52 PM EasternExtended Trading$5.00 +0.18 (+3.71%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Cue Biopharma NASDAQ:CUE$0.69 0.00 (-0.58%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$0.69 +0.00 (+0.58%) As of 07/3/2025 04:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Kalaris Therapeutics NASDAQ:KLRS$2.50 -0.06 (-2.34%) As of 07/3/2025 01:00 PM EasternAllovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.Renovaro NASDAQ:RENB$0.28 0.00 (-0.47%) Closing price 07/3/2025 03:53 PM EasternExtended Trading$0.29 +0.01 (+3.96%) As of 07/3/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case How a Government Loan Changes the Game for Plug Power Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
